Press Releases

Date	Title and Summary	Additional Formats
Toggle SummaryMay182015	Fate Therapeutics Announces Proposed Public Offering of Common Stock SAN DIEGO , May 18, 2015 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (Nasdaq:FATE), a biopharmaceutical company engaged in the development of programmed cellular therapeutics for the treatment of severe, life-threatening diseases, today announced that it has commenced an underwritten public Read All »	View HTML Fate Therapeutics Announces Proposed Public Offering of Common Stock 20.8 KB
Toggle SummaryDec122017	Fate Therapeutics Announces Proposed Public Offering of Common Stock SAN DIEGO, Dec. 12, 2017 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, today announced that it has commenced an underwritten public offering Read All »	View HTML Fate Therapeutics Announces Proposed Public Offering of Common Stock 379.4 KB
Toggle SummarySep112019	Fate Therapeutics Announces Proposed Public Offering of Common Stock SAN DIEGO , Sept. 11, 2019 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “ Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, today announced that it has Read All »	View HTML
Toggle SummarySep202018	Fate Therapeutics Announces Proposed Public Offering of Common Stock SAN DIEGO , Sept. 20, 2018 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, today announced that it has commenced an underwritten public Read All »	View HTML
Toggle SummaryJan042021	Fate Therapeutics Announces Proposed Public Offering of $350 Million of Common Stock SAN DIEGO , Jan. 04, 2021 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “ Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, today announced that it has Read All »	View HTML
Toggle SummaryDec132011	Fate Therapeutics Announces Promising Data From Phase 1B Study of ProHema at the 2011 American Society of Hematology Annual Conference Data Support the Potential Benefit of a Novel Ex Vivo Cell Modulation Approach to Improving Engraftment in Patients Undergoing Umbilical Cord Blood Transplantation Read All »	View HTML Fate Therapeutics announces promising data from Phase 1B study of ProHema at the 2011 American Society of Hematology Annual Conference 15.3 KB
Toggle SummaryNov222016	Fate Therapeutics Announces Private Financing SAN DIEGO, Nov. 22, 2016 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, today announced that it has entered into a definitive securities purchase agreement Read All »	View HTML Fate Therapeutics Announces Private Financing 15.2 KB
Toggle SummaryJan062021	Fate Therapeutics Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants SAN DIEGO , Jan. 05, 2021 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “ Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, today announced the pricing Read All »	View HTML
Toggle SummaryJun092020	Fate Therapeutics Announces Pricing of Public Offering of Common Stock SAN DIEGO , June 09, 2020 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “ Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, today announced the pricing Read All »	View HTML
Toggle SummaryMay202015	Fate Therapeutics Announces Pricing of Public Offering of Common Stock SAN DIEGO , May 20, 2015 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (Nasdaq:FATE), a biopharmaceutical company engaged in the development of programmed cellular therapeutics for the treatment of severe, life-threatening diseases, today announced the pricing of an underwritten public offering of Read All »	View HTML Fate Therapeutics Announces Pricing of Public Offering of Common Stock 148.1 KB

DISCLOSURE NOTICE: The information contained in each press release is as of the date of the respective press release. The Company assumes no obligation to update any information or forward-looking statement contained in any press release as a result of new information or events or developments arising after the date of such press release.